{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=31&q=HNSCC", "query": { "q": "HNSCC", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 1323, "total_pages": 133, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=32&q=HNSCC&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=30&q=HNSCC&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T12:14:10.872Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03194373", "title": "Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2017-10-12", "completion_date": "2020-03-17", "has_results": true, "last_update_posted_date": "2021-04-12", "last_synced_at": "2026-10-16T12:14:10.872Z", "location_count": 3, "location_summary": "Indianapolis, Indiana • Ann Arbor, Michigan • Nashville, Tennessee", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03194373" }, { "nct_id": "NCT00897988", "title": "DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "mutation analysis", "type": "GENETIC" }, { "name": "polyacrylamide gel electrophoresis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 40, "start_date": "2006-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-03-14", "last_synced_at": "2026-10-16T12:14:10.872Z", "location_count": 3, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00897988" }, { "nct_id": "NCT03405142", "title": "Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Head and Neck Cancer" ], "interventions": [ { "name": "Panitumumab-IRDye800", "type": "DRUG" }, { "name": "Lymphoseek", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eben Rosenthal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 3, "start_date": "2019-08-01", "completion_date": "2021-04-27", "has_results": true, "last_update_posted_date": "2022-11-10", "last_synced_at": "2026-10-16T12:14:10.872Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03405142" }, { "nct_id": "NCT06998069", "title": "Head and Neck Cancer Study Project in the Geriatric Population", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Neoplasms" ], "interventions": [ { "name": "Arm I Carboplatin, Paclitaxel, Pembrolizumab", "type": "DRUG" }, { "name": "Arm II Carboplatin, Paclitaxel, Cetuximab", "type": "DRUG" }, { "name": "Arm III Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 20, "start_date": "2025-08-27", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-16T12:14:10.872Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT06998069" }, { "nct_id": "NCT03521570", "title": "Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "IMRT", "type": "RADIATION" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2018-06-28", "completion_date": "2023-09-07", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-16T12:14:10.872Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Cleveland, Ohio • Milwaukee, Wisconsin", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03521570" }, { "nct_id": "NCT03574792", "title": "Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8" ], "interventions": [ { "name": "Gabapentin", "type": "DRUG" }, { "name": "Methadone", "type": "DRUG" }, { "name": "Oxycodone", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Venlafaxine", "type": "DRUG" }, { "name": "Venlafaxine Hydrochloride Extended Release", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2018-05-03", "completion_date": "2021-11-11", "has_results": true, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-16T12:14:10.872Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03574792" }, { "nct_id": "NCT05359692", "title": "INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Head and Neck Squamous Cell Carcinoma", "Advanced Malignancies", "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "INCAGN01876", "type": "BIOLOGICAL" }, { "name": "retifanlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2023-03-01", "completion_date": "2025-01-11", "has_results": false, "last_update_posted_date": "2023-09-15", "last_synced_at": "2026-10-16T12:14:10.872Z", "location_count": 17, "location_summary": "Birmingham, Alabama • La Jolla, California • Palo Alto, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05359692" }, { "nct_id": "NCT05120947", "title": "Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Resectable Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "42 Gy Radiation Therapy", "type": "RADIATION" }, { "name": "39 Gy Radiation Therapy", "type": "RADIATION" }, { "name": "32.5 Gy Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2021-12-01", "completion_date": "2025-11-22", "has_results": true, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-10-16T12:14:10.872Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05120947" }, { "nct_id": "NCT04428333", "title": "Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms, Head and Neck" ], "interventions": [ { "name": "Feladilimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Platinum based chemotherapy", "type": "DRUG" }, { "name": "Fluorouracil (5FU)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2020-08-12", "completion_date": "2023-09-19", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-10-16T12:14:10.872Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04428333" }, { "nct_id": "NCT03564691", "title": "Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "MK-4830", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "MK-4830A", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 470, "start_date": "2018-07-11", "completion_date": "2025-09-26", "has_results": false, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-10-16T12:14:10.872Z", "location_count": 9, "location_summary": "San Francisco, California • Detroit, Michigan • St Louis, Missouri + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03564691" } ] }